Wells Fargo & Company Cardiol Therapeutics Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 3,000 shares of CRDL stock, worth $6,270. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,000Holding current value
$6,270% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding CRDL
# of Institutions
37Shares Held
6.63MCall Options Held
71.7KPut Options Held
0-
Mmcap International Inc. Spc Grand Cayman, E92.57MShares$5.36 Million0.7% of portfolio
-
Tejara Capital LTD London, X01.64MShares$3.44 Million1.09% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD1.3MShares$2.72 Million0.41% of portfolio
-
Lion Street Advisors, LLC253KShares$529,3570.19% of portfolio
-
Cambridge Investment Research Advisors, Inc.129KShares$269,0720.0% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $129M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...